C4 Therapeutics (CCCC)
(Real Time Quote from BATS)
$6.50 USD
+0.06 (0.93%)
Updated Jul 26, 2024 03:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Income Statements
Fiscal Year end for C4 Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 21 | 31 | 46 | 33 | 21 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 21 | 31 | 46 | 33 | 21 |
Selling & Adminstrative & Depr. & Amort Expenses | 160 | 161 | 128 | 94 | 57 |
Income After Depreciation & Amortization | -139 | -130 | -82 | -60 | -35 |
Non-Operating Income | 9 | 0 | 0 | -6 | 0 |
Interest Expense | 1 | -1 | 2 | 1 | -2 |
Pretax Income | -131 | -128 | -84 | -67 | -33 |
Income Taxes | 1 | 0 | 0 | -1 | 1 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -132 | -128 | -84 | -66 | -34 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -132 | -128 | -84 | -66 | -34 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -141 | -126 | -78 | -59 | -34 |
Depreciation & Amortization (Cash Flow) | -2 | 3 | 4 | 2 | 2 |
Income After Depreciation & Amortization | -139 | -130 | -82 | -60 | -35 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 49.64 | 48.86 | 46.04 | 11.37 | NA |
Diluted EPS Before Non-Recurring Items | -2.67 | -2.62 | -1.82 | -5.83 | NA |
Diluted Net EPS (GAAP) | -2.67 | -2.62 | -1.82 | -5.83 | NA |
Fiscal Year end for C4 Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 3.04 | 3.26 | 11.07 | 2.66 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 3.04 | 3.26 | 11.07 | 2.66 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 35.26 | 40.69 | 38.88 | 40.24 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -32.22 | -37.43 | -27.81 | -37.58 |
Non-Operating Income | NA | 3.86 | 2.95 | 1.94 | 2.25 |
Interest Expense | NA | 0.00 | 0.00 | 0.17 | 0.60 |
Pretax Income | NA | -28.36 | -34.48 | -26.03 | -35.92 |
Income Taxes | NA | 0.00 | 0.28 | 1.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -28.36 | -34.75 | -27.04 | -35.92 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -28.36 | -34.75 | -27.04 | -35.92 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 68.43 | 49.64 | 49.21 | 49.06 |
Diluted EPS Before Non-Recurring Items | NA | -0.41 | -0.68 | -0.55 | -0.73 |
Diluted Net EPS (GAAP) | NA | -0.41 | -0.68 | -0.55 | -0.73 |